Pilar Hernández-Jiménez

Dr. Pilar Hernández-Jiménez

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
LCLaura Corbella
Laura Corbella
JPJorge Boán Pérez
Jorge Boán Pérez
RSRafael San-Juan
Rafael San-Juan
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
OCOctavio Carretero
Octavio Carretero
JAJose Maria Aguado
Jose Maria Aguado

23 October 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
PHPilar Hernández-Jiménez
Pilar Hernández-Jiménez
FLFrancisco Lopez-Medrano
Francisco Lopez-Medrano
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
JSJ. Tiago Silva
J. Tiago Silva
LCLaura Corbella
Laura Corbella
JAJose Maria Aguado
Jose Maria Aguado
Background: Pseudomonas aeruginosa (PSA) infection often occurs in immunocompromised patients, which also face an increased risk of multidrug-resistant (MDR) bacteria. A deeper knowledge of the risk factors for MDR-PSA infection in this patient population may help to choose appropriate empirical antibiotic therapy. Methods: a single-center case-control (1:2) retrospective study that included 48 patients with underlying immunosuppression developing MDR-PSA infection (cases) and 96 patients also immunocompromised that were infected with non-MDR-PSA (controls) was conducted. Both groups were matched by site of infection, clinical features and type of immunosuppression. Risk factors for MDR-PSA were assessed by logistic regression. Clinical outcomes were also compared between both groups. Results: immunosuppression was due to solid cancer in 63 (43.8%) patients, solid organ transplantation in 39 (27.1%), hematological disease in 35 (24.3%) and other causes in 7 (4.9%). Independent risk factors for MDR-PSA infection were diabetes mellitus (odds ratio [OR]: 4.74; 95% confidence interval [CI]: 1.63–13.79; p = 0.004), antibiotic therapy in the previous 3 months (OR: 5.32; 95% CI: 1.93–14.73; p = 0.001), previous MDR-PSA colonization (OR: 42.1; 95% CI: 4.49–394.8; p = 0.001) and septic shock (OR: 3.73; 95% CI: 1.36–10.21; p = 0.010). MDR-PSA cases were less likely to receive adequate empirical therapy (14 [29.2%] vs. 69 [71.9%]; p < 0.001). 30-day clinical improvement was less common in MDR-PSA cases (25 [52.1%] vs. 76 [79.2%]; p = 0.001). Conclusions: diabetes mellitus, previous MDR-PSA colonization, prior receipt of antibiotics and septic shock acted as risk factors for developing MDR-PSA infections in immunocompromised patients, who have a poorer outcome than those infected with non-MDR-PSA strains.

23 March 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
MMMikel Mancheño-Losa
Mikel Mancheño-Losa
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
PHPilar Hernández-Jiménez
Pilar Hernández-Jiménez
Natividad BenitoNatividad Benito
Natividad Benito
Óscar MurilloÓscar Murillo
Óscar Murillo
Prosthetic joint infections are considered difficult to treat they needing aggressive surgery and long antimicrobial treatments. However, the exact duration of these therapies has been established empirically. In the last years, several studies have explored the possibility of reducing the length of treatment in this setting, with conflicting results. In this narrative review, we critically appraise the published evidence, considering the different surgical approaches (implant retention [DAIR] and one-step and two-step exchange procedures) separately. In patients managed with DAIR, usually treated for at least 12 weeks, a large, randomized trial failed to show that 6 weeks were non-inferior. However, another randomized clinical trial supports the use of 8 weeks, as long as the surgical conditions are favorable and antibiotics with good antibiofilm activity can be administered. In patients managed with a two-step exchange procedure, usually treated during 6 weeks, a randomized clinical trial showed the efficacy of a 4-week course of antimicrobials. Also, the use of local antibiotics may allow the use of even shorter treatments. Finally, in the case of one-step exchange procedures, there is a trend towards reducing the length of therapy, and the largest randomized clinical trial supports the use of 6 weeks of therapy.

7 October 2016 in Medicina Clinica
Verified
Journal Article
Closed access
PHPilar Hernández-Jiménez
Pilar Hernández-Jiménez
DCDiaz-Pedroche Carmen
Diaz-Pedroche Carmen
JLJaime Laureiro
Jaime Laureiro
OMOlaya Madrid
Olaya Madrid
EMEstela Martín
Estela Martín
CLCarlos Lumbreras
Carlos Lumbreras

21 March 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LCLaura Corbella
Laura Corbella
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
MRMaria Ruiz-Ruigómez
Maria Ruiz-Ruigómez
IRIsabel Rodríguez-Goncer
Isabel Rodríguez-Goncer
JSJosé Tiago Silva
José Tiago Silva
RSRafael San-Juan
Rafael San-Juan
To describe the determinants of outcome of infections due to oxacillinase-48 (OXA-48) carbapenemase-producing Klebsiella pneumoniae (OXA-48-Kp). A retrospective cohort study of 117 episodes of OXA-48-Kp infection were conducted. Multivariate Cox models identified factors predicting 14-day clinical response and 30-day all-cause mortality. A total of 77 (65.8%) isolates were susceptible to imipenem/meropenem. The 14-day clinical response and 30-day mortality rates were 41.9% and 28.2%. Catheter-related bloodstream infection (adjusted hazard ratio [aHR]: 8.33; 95% confidence interval [95%CI]: 3.19-21.72; P-value <0.001), urinary tract infection (aHR: 3.04; 95%CI: 1.39-6.66; P-value = 0.006) and early appropriate treatment (aHR: 1.77; 95%CI: 0.97-3.22; P-value = 0.064) predicted clinical response, whereas severe sepsis had a deleterious impact (aHR: 0.22; 95%CI: 0.10-0.50; P-value <0.001). Lower respiratory tract infection (aHR: 6.58; 95%CI: 2.83-15.29; P-value <0.001) and bloodstream infection (aHR: 2.33; 95%CI: 1.05-5.15; P-value = 0.037) were associated with 30-day mortality, whereas definitive therapy including ≥1 active agent (aHR: 0.26; 95%CI: 0.11-0.63; P-value = 0.003) and source control (aHR: 0.35; 95%CI: 0.14-0.91; P-value = 0.030) were protective. Combination therapy did not seem to be associated with better outcomes. Appropriate antimicrobial treatment was protective for 30-day mortality in OXA-48-Kp infections. Carbapenems are usually active, whereas combination therapy appeared not to confer additional benefit.

23 March 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
PHPilar Hernández-Jiménez
Pilar Hernández-Jiménez
FLFrancisco López-Medrano
Francisco López-Medrano
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
JSJose T. Silva
Jose T. Silva
LCLaura Corbella
Laura Corbella
JAJose Maria Aguado
Jose Maria Aguado
Multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) constitutes an emerging health problem. A predictive score of MDR-PSA infection would allow an early adaptation of empirical antibiotic therapy. We performed a single-centre case-control (1:2) retrospective study including 100 patients with MDR-PSA and 200 with a non-MDR-PSA infection. Cases and controls were matched by site of infection, clinical characteristics and immunosuppression. A point risk score for prediction of MDR-PSA infection was derived from a logistic regression model. Secondary outcomes (clinical improvement, complications and discharge) were also compared. Cases with MDR-PSA infection were younger than controls (67.5 vs. 73.0 y; P = 0.031) and have more frequent cirrhosis (9% vs. 2%; P = 0.005). Independent risk factors for MDR-PSA infection were prior antibiotic treatment (80% vs. 50.5%; P < 0.001), prior colonisation with MDR bacteria (41% vs. 13.5%; P < 0.001), hospital-acquired infection (63% vs. 47%; P = 0.009) and septic shock at diagnosis (33% vs. 14%; P < 0.001). Adequate therapy was less frequent in MDR-PSA infections (31% vs. 66.5% for empirical therapy; P < 0.001). The risk score included: previous MDR-PSA isolation (11 points), prior antibiotic use (3 points), hospital-acquired infection (2 points) and septic shock at diagnosis (2 points). It showed an area under the curve of 0.755 (95% CI: 0.70-0.81) and allowed to classify individual risk into various categories: 0-2 points (<20%), 3-5 points (25%-45%), 7-11 points (55%-60%), 13-16 points (75%-87%) and a maximum of 18 points (93%). Infections due to MDR-PSA have a poorer prognosis than those produced by non-MDR-PSA. Our score could guide empirical therapy for MDR-PSA when P. aeruginosa is isolated.